PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS

  • issa I
  • Hammam A
  • Sakr H
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Human phosphatidyl inositol mannoside kinases (Pim kinases) are important biological target for discovery of new anticancer agents. In addition, Pyrimidines have a good contribution as building blocks of many anticancer agents. Hence, a literature survey about Pim kinases inhibitors and pyrimidine-based anticancer agents have been achieved. In this survey, we introduced Pim kinase inhibitors under clinical assessment including imidazo[1,2-b]pyridazines, isatins, thiazolidine-2,4-diones, pyridinamines, and diaminopyrazoles. In addition, Pim kinase inhibitors under development were presented. These compounds include pyridine-quinolines, benzimidazoles indoles, cyano pyridines, pyridothieno[3,2-d]pyrimidin-4-ones, oxadiazole, and 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones. Furthermore, different pyrimidine-based anticancer agents have been discussed.

Cite

CITATION STYLE

APA

issa, ibrahim, Hammam, A., Sakr, H., & Ayyad, R. (2023). PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS. Al-Azhar Journal of Pharmaceutical Sciences, 67(1), 68–83. https://doi.org/10.21608/ajps.2023.311247

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free